This study, called RadiaNCe Lung X, is for people with advanced non-small cell lung cancer (NSCLC) that has spread (metastatic) and has specific genetic changes (driver mutations). It is testing if giving radiation therapy to the main tumor in the lung before starting a targeted therapy called a tyrosine kinase inhibitor (TKI) can help delay the cancer from growing or spreading. You would first receive radiation therapy, and then, if you have a driver mutation, you would receive a standard TKI medication. The study aims to see if this approach can extend the time until the cancer progresses, with this time measured for up to 18 months after starting TKI treatment. The study is currently recruiting up to 34 participants.

Study design

This is a single-arm, phase II study, meaning all participants receive the same treatment sequence, and it plans to enroll up to 34 patients.

What's involved

You would receive radiation therapy, followed by a standard-of-care TKI medication. While on TKI therapy, your disease progression will be checked every three months.

Compensation

Not stated in the trial record.

Follow-up

Your progression-free survival will be measured from the start of TKI treatment up to 18 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.